<html><head></head><body><h1>Rynatan</h1><p class="drug-subtitle"><b>Generic Name:</b> phenylephrine tannate and chlorpheniramine tannate<br/>
<b>Dosage Form:</b> tablet<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Side Effects</li>
<li>Dosage</li>
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li>Pregnancy</li>
<li>Reviews</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li>Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Overdosage</li>
<li class="ddc-toggle-hidden">Dosage and Administration</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
</ul><p>The Rynatan brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.</p><h2>Description</h2><p class="First">Rynatan<span class="Sup">®</span> Tablets are an antihistamine/nasal decongestant combination. Each tablet contains:<br/>
Phenylephrine Tannate            25 mg<br/>
Chlorpheniramine Tannate        9 mg<br/>
Other ingredients: corn starch, dibasic calcium phosphate, magnesium stearate, methylcellulose, polygalacturonic acid, povidone, talc.</p><h2>Clinical Pharmacology</h2><p class="First">Rynatan<span class="Sup">®</span> Tablets combine the sympathomimetic decongestant effect of phenylephrine with the antihistaminic action of chlorpheniramine.</p><h2>Indications and Usage</h2><p class="First">Rynatan<span class="Sup">®</span> Tablets are indicated for symptomatic relief of the coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease.</p><h2>Contraindications</h2><p class="First">Rynatan<span class="Sup">®</span> Tablets are contraindicated for newborns, nursing mothers and patients sensitive to any of the ingredients or related compounds.</p><h2>Warnings</h2><p class="First">Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma or prostatic hypertrophy. Use with caution or avoid use in patients taking monoamine oxidase (MAO) inhibitors, or within 14 days of stopping such treatment. This product contains an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).</p><h2>Precautions</h2><p class="First"><span class="Italics">General:</span> Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation.</p><p><span class="Italics">Information for patients:</span> Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery while using this product. Patients should be warned not to use this product if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product.</p><p><span class="Italics">Drug interactions:</span> MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents.</p><p><span class="Italics">Carcinogenesis, mutagenesis, impairment of fertility:</span> No long term animal studies have been performed with Rynatan<span class="Sup">®</span> Tablets.</p><p><span class="Italics">Pregnancy:</span> Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with Rynatan<span class="Sup">®</span> Tablets. It is also not known whether Rynatan<span class="Sup">®</span> Tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Rynatan<span class="Sup">®</span> Tablets should be given to a pregnant woman only if clearly needed.</p><p><span class="Italics">Nursing mothers:</span> Rynatan<span class="Sup">®</span> Tablets should not be administered to a nursing woman.</p><h2>Adverse Reactions</h2><p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or <span class="Bold"><span class="Italics">www.fda.gov/medwatch</span></span>.</span></p><p>Adverse effects associated with Rynatan<span class="Sup">®</span> Tablets at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare.</p><h2>Overdosage</h2><p class="First"><span class="Italics">Signs &amp; symptoms:</span> May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent.</p><p><span class="Italics">Treatment:</span> Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered.</p><h2>Dosage and Administration</h2><p class="First">Administer the recommended dose every 12 hours.</p><p>Rynatan<span class="Sup">®</span> Tablets: Adults — 1 or 2 tablets.</p><h2>How Supplied</h2><p class="First">Rynatan<span class="Sup">®</span> Tablets (phenylephrine tannate 25 mg, chlorpheniramine tannate 9 mg): buff-colored, capsule-shaped, scored on one side and imprinted Rynatan 707 on the other side. The tablets are available in bottles of 100 (NDC 0037-0707-10).</p><p><span class="Italics">Storage:</span> Store at controlled room temperature 20°-25°C (68°-77°F). Protect from moisture.</p><p>Dispense in a tight container.</p><p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or <span class="Bold"><span class="Italics">www.fda.gov/medwatch</span></span>.</span></p><p>U.S. Patent 6,037,358<br/>
Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ, U.S.A.</p><p>U.S. Patents 5,599,846; 5,663,415</p><p>MEDA Pharmaceuticals<span class="Sup">®</span><br/>
Meda Pharmaceuticals Inc.<br/>
Somerset, New Jersey 08873-4120</p><p>Printed in U.S.A.                                             Rev. 1/09</p><h2>Package Label - Principal Display Panel – 100 Tablet Bottle, Rynatan TitratableTablets</h2><p class="First">NDC 0037-0707-10</p><p><span class="Bold">Rynatan<span class="Sup">®</span></span></p><p>(phenylephrine tannate,</p><p>chlorpheniramine tannate)</p><p>TITRATABLE TABLETS</p><p>100 Tablets</p><p>Each tablet contains:</p><p>Phenylephrine Tannate, 25 mg</p><p>Chlorpheniramine Tannate, 9 mg</p><p>U.S. Patent 6,037,358</p><p><span class="Bold">R<span class="Sub">x</span> only</span></p><p><span class="Bold">MEDA</span></p><p><span class="Bold">Pharmaceuticals™</span></p><p>LB-070710-06                Rev. 2/08</p><p><span class="Bold">Usual Dose:</span> See package insert.</p><p>Store at controlled room temperature</p><p>20°-25°C (68°-77°F).</p><p>Protect from moisture.</p><p>Dispense in a tight container.</p><p>Produced under license from</p><p>JFC Technologies</p><p>Bound Brook, NJ U.S.A.</p><p>U.S. Patents 5,599,846;5,663,415</p><p><span class="Bold">MEDA</span></p><p><span class="Bold">Pharmaceuticals™</span></p><p><span class="Bold">Meda Pharmaceuticals Inc.</span></p><p>Somerset, New Jersey 08873-4120</p><p></p><h2>More about Rynatan (chlorpheniramine / phenylephrine)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>5 Reviews</li>
<li>Drug class: upper respiratory combinations</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Allergic Rhinitis</li>
<li>Cold Symptoms</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>